Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps down

Biocon on Friday said Managing Director and Chief Executive Officer Siddharth Mittal will step down from his role at the close of business hours on March 31, transitioning to another leadership position within the group, while Shreehas Pradeep Tambe has been appointed as his successor.

Also Read: Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw

The board has approved the appointment of Tambe—currently CEO and MD of Biocon Biologics—as an additional director effective April 1, 2026, and as CEO and MD for a five-year term, subject to shareholder approval.


With his resignation, Mittal will also cease to be a key managerial personnel of the company. The company said his candidature for the new role within the Biocon Group marks an internal leadership transition.

The appointment of Tambe follows the recommendation of the Nomination and Remuneration Committee and is in line with regulatory requirements, the company said, adding that he is not debarred from holding the office of director by any order of the Securities and Exchange Board of India or any other authority.

Mukesh Kamath steps down as interim CFO; Kedar Upadhye appointed successor effective April 1

The company also announced the resignation of interim Chief Financial Officer Mukesh Kamath, effective close of business hours on March 31, 2026, as he transitions to another role within the Biocon Group.

Also Read: Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classification

The board has approved the appointment of Kedar Narayan Upadhye, currently CFO of Biocon Biologics, as Chief Financial Officer of the company with effect from April 1, 2026.

Biocon share price was trading 2% lower on Friday, as of 12:15 pm, to Rs 371.9.